Clinical Trial Update: BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a BCMA/GPRC5D-targeted CAR-T therapy for refractory multiple myeloma. The study is not yet recruiting and is sponsored by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA/GPRC5D CAR-T therapy (BCMA/GPRC5D CAR-T cells)

Snippet

Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Conditions: Multiple Myeloma Refractory | EARLY_Phase 1 | Status: NOT_YET_RECRUITING